Ivabradine in the family physician’s practice

Ivabradine is a medicinal product with a unique mechanism of action that distinguishes it from traditional heart-rate-lowering agents. This article provides a systematic analysis of the therapeutic effects of ivabradine and summarizes current clinical data. It examines the drug's role in heart rate control, its impact on left ventricular diastolic function, and its efficacy in cases of acute and chronic heart failure (CHF), stratified by ejection fraction. It has been shown that ivabradine is most effective in patients with sinus tachycardia and CHF with reduced ejection fraction, whereas its clinical benefit in cases of CHF with preserved ejection fraction has not been established. The drug is well tolerated and does not cause hypotension; however, caution should be exercised when administering it to patients with baseline bradycardia or those taking CYP3A4 inhibitors.